Burns Clinical Trial
— FASTOfficial title:
A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
NCT number | NCT00061633 |
Other study ID # | I6424-202a |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | June 2003 |
Est. completion date | January 2004 |
Verified date | January 2019 |
Source | Cumberland Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients.
Status | Completed |
Enrollment | 169 |
Est. completion date | January 2004 |
Est. primary completion date | January 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have a diagnosis of one of the following complicated skin and skin structure infections with either a suspected or confirmed Gram positive organism as the major cause of the infection: - major abscess requiring surgical incision and drainage - infected burn (see exclusion criteria for important qualifications) - deep/extensive cellulitis - infected ulcer (see exclusion criteria for important qualifications) - wound infections - Patients must be expected to require at least 4 days of intravenous antibiotic treatment Exclusion Criteria: - Previous systemic antibacterial therapy (with the exception of aztreonam and metronidazole) for > 24 hours within 7 days prior to the first dose of study medication unless the pathogen was resistant to prior treatment or the patient was a treatment failure (no clinical improvement after 3 days). - Burns involving > 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis. |
Country | Name | City | State |
---|---|---|---|
United States | eStudy Site, 3450 Bonita Road, Ste 201 | Chula Vista | California |
Lead Sponsor | Collaborator |
---|---|
Cumberland Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population | Cure: Resolution of clinically significant signs, symptoms associated with the skin infection present at study admission or improvement to the extent that the infectious process had been controlled and no further therapy with study medication was necessary. Failure: Inadequate response to study therapy or the need for significant surgical management (e.g. more than just routine debridement) of the infection site following antibiotic therapy and prior to the Test-of-Cure (TOC) visit. Indeterminate: Inability to determine outcome. |
7-14 days following end of antibiotic treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05023135 -
DeepView SnapShot Portable (DV-SSP): Device Training Study
|
||
Completed |
NCT05276869 -
Reliability and Feasibility of WeeFIM Instrument to Measure Functional Independence in Pediatric Burns
|
||
Completed |
NCT04548635 -
VR for Burn Dressing Changes at Home
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06076031 -
Effects of Applying Streaming Media on Reducing Pain in Patient With Second-degree Burn During Changing Dressing
|
N/A | |
Recruiting |
NCT05084248 -
Vitamin D Deficiency in Adults Following a Major Burn Injury
|
Phase 4 | |
Completed |
NCT03113253 -
TRANexamic Acid to Reduce Bleeding in BURN Surgery
|
Phase 4 | |
Recruiting |
NCT04090424 -
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Withdrawn |
NCT03159182 -
Study of Silicone Material Inserts To Treat Burn Scars
|
N/A | |
Recruiting |
NCT02904941 -
Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns
|
N/A | |
Completed |
NCT02681757 -
Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns
|
N/A | |
Recruiting |
NCT01812941 -
Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients
|
N/A | |
Completed |
NCT01437852 -
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
|
Phase 1 | |
Completed |
NCT01214811 -
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
|
Phase 3 | |
Completed |
NCT01061502 -
Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds
|
Phase 1/Phase 2 | |
Terminated |
NCT00822796 -
Thermogard™ Efficacy Trial
|
N/A | |
Terminated |
NCT00824681 -
Effect of Music Therapy on Families of Burn Patients
|
Phase 1 | |
Terminated |
NCT00634166 -
Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
|
Phase 4 | |
Terminated |
NCT00464386 -
Continuous Glucose Monitoring (POC) in the ICU
|
N/A | |
Withdrawn |
NCT00216983 -
Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding
|
N/A |